ABSTRACT
Thyroid cancer is one of the most common endocrine malignancies. It has an
increasing population incidence (1,2). The annual incidence per 100 individuals
ranges from 1.2 to 2.6 in men and from 2.0 to 3.8 in women. Most of the tumors
have a relatively indolent clinical course. However, subgroups of patients may
have an aggressive clinical course or a high risk of developing recurrence (3).
The optimum treatment for thyroid carcinoma is still debated and a number of
controversies exist with respect to the extent of surgery, use of radioactive
iodine, and postoperative thyroxine suppression.
